Benchmarking mismatch repair testing for patients with cancer receiving immunotherapy.
Journal
Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617
Informations de publication
Date de publication:
20 Dec 2023
20 Dec 2023
Historique:
received:
13
10
2023
revised:
30
11
2023
accepted:
01
12
2023
medline:
2
1
2024
pubmed:
2
1
2024
entrez:
29
12
2023
Statut:
aheadofprint
Résumé
Immunohistochemistry (IHC) is currently the first-line test for mismatch repair deficiency (MMR-D). Bou Farhat et al. show that mismatch repair (MMR) mutation signature by next-generation sequencing is a highly sensitive assay capable of detecting MMR-D cases that are missed in 1% and 5% of patients with MMR-D colorectal cancer (CRC) and endometrial cancer (EC), respectively. Patients with MMR-D tumors missed by IHC have similar clinical outcomes to patients with MMR-D by both IHC and mutation signature.
Identifiants
pubmed: 38157866
pii: S1535-6108(23)00420-8
doi: 10.1016/j.ccell.2023.12.001
pii:
doi:
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests D.J.K. reports receiving grant support from Genentech, Revolution Medicines, and AADI and serving as a consultant for Genentech, AADI, Guidepoint, Bridgebio, William Blair, and Slingshot Insights. A.H.N. receives honoraria from OncLive, TEMPUS, and Korean Society for Medical Oncology and consulting fees from Guidepoint global. L.M.S. reports serving as a consultant for Genentech, Lilly, and AstraZeneca and receiving grant funding from Genentech and Bristol Myers Squibb. E.B.F. reports serving as a clinical research coordinator for AADI.